Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of ...

Far from the dizzying auctions, splashy galas and angling dealers, a precious gift sheds light on a gentler way the art world ...

The European stock markets closed lower in Tuesday trading as The Stoxx Europe fell 0.43%, Germany's DAX was down 0.67%, the FTSE in London was off 0.13%, France's CAC dropped 0.67%, and the Swiss ...

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...

GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...